Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Trial Pipeline
Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection
NCT05753215
Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men
NCT04175678
Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women
NCT04037605
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
NCT03153319
Effect of Inorganic Nitrate Supplement on Blood Pressure
NCT03909789
Time Limited Trials to Reduce Non-Beneficial Intensive Care Unit Treatments
NCT04181294
Comparison of Two Application Techniques for LET Gel
NCT04203225
The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease
NCT02845752
Safety of Nitroglycerin for Field Treatment of STEMI
NCT02407002
Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men
NCT01382069
Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates
NCT01404247
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
NCT01268553
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
NCT00860847
Intrauterine Contraceptive Device (IUD) Placement at Time of C-Section
NCT00733278
The Significance of Funguria in Hospitalized Patients
NCT00787085
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 4 |
Therapeutic Areas
What the Pipeline for Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Shows
According to the ClinicalTrials.gov registry, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is linked to 15 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 11 are already marked complete, representing roughly 73% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center reports 5 late-stage studies (Phase 3 and Phase 4 combined) and 5 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is LET with 1 linked trial, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.